Omada Health Earnings Call Highlights Profitable Surge

Omada Health, Inc. ((OMDA)) has held its Q2 earnings call. Read on for the main highlights of the call.

Omada Health’s latest earnings call painted a picture of a digital health company hitting its stride, with record revenue, a sharp swing to profitability, and widening margins underscoring strong operational execution. Management acknowledged seasonal and execution risks, particularly around GLP-1 coverage and newer channels, but emphasized disciplined investment and a clear path to scaling its growing pipeline.

Record Revenue and a Turn to Profitability

Omada posted Q2 revenue of $88 million, up 43% year over year and 13% sequentially, marking its strongest quarter to date. The company flipped from a GAAP net loss of roughly $5 million a year ago to a GAAP net income of $5 million and delivered a record $11 million in adjusted EBITDA, an $11 million improvement versus last year.

Membership Growth Extends Omada’s Reach

Total membership reached about 1.1 million at quarter end, a 45% increase from the prior year, highlighting robust demand for the company’s digital care programs. Omada has now served more than 2 million members over its history and estimates more than 25 million eligible covered lives, underscoring a large addressable base.

Gross Margins Push Well Above Long-Term Targets

GAAP gross margin expanded to 73%, roughly 700 basis points higher than a year earlier, while non-GAAP gross margin reached 74%, up about 600 basis points. Management indicated confidence that margins can sustainably remain above the previously stated long-term target of 70%, signaling durable structural improvements.

Unit Economics Strengthen as Members Stay Engaged Longer

Revenue per member over the trailing 12 months edged up to $284 from $279, but the bigger gain came from efficiency and engagement. Cost to serve per member fell more than 10% year over year, and members are staying active about 10% longer, supporting more billable months and enhancing lifetime value.

Operating Leverage and Expense Discipline Take Hold

Non-GAAP operating expenses fell to 62% of revenue from 68% a year ago, showing that costs are growing slower than sales. The company generated roughly a 41% incremental adjusted EBITDA margin in the quarter, demonstrating strong operating leverage as scale builds across the platform.

Balance Sheet Offers Strategic Flexibility

Omada closed the quarter with around $222 million in cash and cash equivalents and carried no debt, providing a solid buffer to fund growth initiatives. This balance sheet strength gives management room to invest in new products, AI capabilities, and channel partnerships without near-term financing pressure.

Product Innovation and Channel Partnerships Gain Traction

The company highlighted momentum in its GLP-1 care track, including a new prescribing program, and a standalone cholesterol product that is seeing early customer uptake. Deeper partnerships with major pharmacy benefit managers and an expanded relationship with HCSC, which will add roughly 1.5 million covered lives in 2027, aim to broaden distribution.

AI Adoption Drives Efficiency and Capacity

Management pointed to AI and machine learning as key contributors to lower care delivery costs and improved productivity within its clinical teams. These tools are boosting coach capacity, sharpening enrollment targeting, and supporting broader operating leverage as the member base expands.

Enrollment Effectiveness Continues to Improve

Omada’s primary email enrollment channel saw conversion improve about 20% year over year, reflecting better targeting and more personalized messaging. Higher conversion from existing channels reduces customer acquisition costs and supports continued growth without heavy marketing spend.

Seasonal Slowdown Expected in the Second Half

Despite the strong first half, management guided investors to expect slower growth in the back half of the year due to normal seasonality, as Q1 is typically the strongest enrollment period. The company’s updated outlook incorporates a more measured H2 trajectory following an exceptionally strong start to the year.

Near-Term EBITDA Margins to Moderate

Q2’s roughly 12% EBITDA margin sits above what management expects for the second half, as earlier hiring and investments fully annualize. Operating expenses are projected to remain flat or tick up slightly, leading to sequential margin moderation even as full-year profitability improves.

GLP-1 Coverage Decisions Introduce Demand Uncertainty

Employers are still weighing whether to expand or restrict coverage for GLP-1 medications, creating a mixed and evolving landscape. This uncertainty may influence demand and purchasing cycles for portions of Omada’s GLP-1-focused offerings, even as the broader member base remains diversified.

Early-Stage Channels Bring Execution Risk

Several PBM partnerships and Omada’s first prescribing partner are still in early commercialization phases, with one PBM channel just beginning its sales motion. While initial signs are encouraging, management acknowledged limited near-term visibility and the need for consistent execution to ramp these channels.

Pipeline Conversion Critical as Growth Comps Tighten

With strong growth already logged in 2025, the company emphasized that converting a sizable pipeline and channel opportunities in H2 and 2027 will be crucial. Management plans to provide more detail on its long-term framework and execution roadmap at an upcoming Investor Day.

GLP-1 Members Still a Minority of the Base

Historically, Omada disclosed about 150,000 GLP-1 members out of roughly 887,000 total, putting GLP-1 penetration below 20% of its member base. This suggests meaningful room for expansion in GLP-1-related programs while highlighting that the business is not yet overly dependent on that segment.

Raised Guidance Underscores Confidence Despite Seasonality

Omada raised its full-year 2026 outlook to $334 million to $340 million in revenue, up from a prior range of $322 million to $330 million, with the midpoint implying about 30% growth versus 2025. Adjusted EBITDA guidance increased to $21 million to $27 million, roughly quadrupling 2025’s midpoint, even as management flagged typical seasonality and investment-related margin pullbacks in the second half.

Omada’s earnings call showcased a company delivering both scale and profitability, with record revenue, expanded margins, and robust membership growth bolstering investor confidence. While second-half moderation, GLP-1 coverage uncertainty, and early-stage channel risks remain, management’s raised guidance and strong balance sheet frame a story of disciplined growth and execution-driven upside.